1 BTC
=
- USD
Spruce Biosciences, Inc. Common Stock
As of May 30, 2026 at 24:05 UTC
Chart
About Spruce Biosciences, Inc. Common Stock
Spruce Biosciences Inc is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with unmet medical needs. The company develops biologics and small-molecule product candidates aimed at addressing diseases with unmet medical needs and limited or no approved therapies. Its product candidate, TA-ERT for the treatment of Mucopolysaccharidosis Type IIIB (MPS IIIB), is a fusion protein comprised of recombinant human alpha-N-acetylglucosaminidase (rhNAGLU) intended as an enzyme replacement therapy for patients who lack rhNAGLU enzyme activity. TA-ERT is designed to restore rhNAGLU enzyme activity in the central nervous system following intracerebroventricular injection and promote clearance of heparan sulfate in the brain.
Market Statistics
Trading Metrics
How to Buy SPRB
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy SPRB
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesU.S. stock futures rose on Tuesday following Monday's decline, with major indices edging higher. Markets are focused on U.S.-Iran negotiations in Islamabad and Kevin Warsh's Fed Chair confirmation hearing. Key stocks in focus include Apple (CEO transition), UnitedHealth (earnings expected), 3M (earnings expected), Amazon (Anthropic partnership expansion), and Spruce Biosciences (stock offering announcement).
The article discusses the rare endocrinology and metabolic disorders market, focusing on hypophosphatasia, congenital adrenal hyperplasia, and severe hypertriglyceridemia. It highlights the challenges faced by patients, the current treatment landscape, and the pipeline of emerging therapies.
Spruce Biosciences (SPRB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).